Lifestyle modifications as therapy for medication refractory post-traumatic headache (PTHA) in the military population of Okinawa

Virginia B. Baker 1*, Kathryn M. Eliasen 2 and Nawaz K. Hack 1

Abstract

Objective: Our aim was 1) to reduce disability, as characterized by headache frequency, duration and severity in patients with post-traumatic headache (PTHA), 2) to reduce the number of medical boards and work limitations in patients with post-traumatic headache, and 3) to reduce use of medical resources and clinic visits related to headache or migraine.

Background: Modifiable risk factors for PTHA include stressful life event, sleep disturbances, and medication overuse. Cognitive-behavioral strategies, biofeedback, and relaxation therapy may have an important role in treatment and preventing progression to chronic post-traumatic headache (CPTHA). There is limited literature and a known practice gap for implementation of these techniques.

Design/methods: An IRB approved project focused on patients who were seen for PTHA and CPTHA. 1) Intervention consisted of lifestyle teaching, cognitive-behavioral therapy and biofeedback, supplemented by decreasing polypharmacy. 2) Patients were followed for 2 years and a retrospective review was conducted for 2 years prior to presentation. 3) Outcome measures included reduction in migraine intensity or frequency, improved quality of life, duty status, and decreased utilization of clinic visits.

Results: Over the course of one year, 221 patients were treated for migraines in the Naval Okinawa Neurology Clinic. Of these, 22 active duty service members and 3 Dependents suffered a mild TBI prior to onset. After intervention, there was a 36% decrease in PTHA frequency, 56% decrease in headache severity and 60% of patients had improved quality of life as compared to the 2 years prior to intervention. Twenty-four percent had reduction in polypharmacy. Appointment frequency for migraine decreased from an average of 6.8 to 2.6 per year.

Conclusions: An implemented program geared towards reducing polypharmacy was shown to improve safety, quality of life and reduce hospitalizations from the burden of migraines. Our systematic approach resulted in quality of life improvements and decreased use of medical resources.

Trial registration: Authors received the approval of NAVMED West, Okinawa Naval Hospital Institutional Review Board on January 13th, 2016. QI.2016.0021.

Keywords: Post-traumatic headache (PTHA), Chronic post-traumatic headache (CPTHA), Lifestyle, Polypharmacy

* Correspondence: virginia.b.baker11.mil@mail.mil
1 Department of Neurology, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20889, USA
Full list of author information is available at the end of the article
Background
Traumatic brain injury (TBI) affects 1.7 million Americans and results in 275,000 hospitalizations per year. Among this population, chronic pain has a prevalence of nearly 40%, the majority due to headaches [1–4]. The International Classification of Headache Disorders, edition 3, defines post-traumatic headache (PTHA) as developing within 7 days of injury to the head. This is further defined as acute versus chronic post-traumatic headache (CTPHA) based on persistence after 3 months [5]. In active duty servicemen with a history of TBI, one study documented nearly 20% had chronic daily headache and 78% had episodic headache [6]. A review of headache after deployment-related TBI noted an even higher occurrence of chronic daily headache, occurring in 44% as compared to 7% of patients who suffered head injury not related to deployment. The progression to chronic migraine is 4–5 times more frequent in the military population, likely due to known psychosocial stressors associated with service. This is compounded by limited preventative measures and lifestyle interventions received in a deployed setting [7].

History of concussion or mild TBI has been shown to correlate with poor mental health outcomes, particularly for those who endorse PTHA [8–11]. Furthermore, it is recognized that psychiatric symptoms can make recovery more difficult [12].

Relaxation training, counseling, cognitive behavioral therapy (CBT) and behavioral therapy have demonstrated efficacy in small controlled trials and retrospective case reports in treatment of post-traumatic headache disorders [8, 13, 14]. Two studies demonstrated significant improvement in headache outcomes, general well-being and up to 50% reduction in self-reported headache days with use of CBT or behavioral therapy [14, 15]. A pilot study performing one-day behavioral intervention on patients with headaches and coinciding anxiety or depression demonstrated notable improvement in the absence of new medication [16]. A systematic review of treatment strategies for PTHA ultimately proposed a treatment model that utilizes behavioral therapy in difficult-to-control headache disorders [17]. However, there is a known practice gap for implementation of these techniques in active duty service members with prior head trauma [18–20].

Presently, there are no FDA approved medications for PTHA or CTPHA and there is no strong evidence for a standardized treatment approach [10, 17, 21]. Yet these conditions are often over-medicated with both prescription and over the counter pharmacotherapies [22, 23]. Medication overuse is especially problematic in the military population, and both TBI and PTSD have been shown to increase the risk for overuse [24–26]. Polypharmacy in the setting PTHA leads to greater disability, increases the chance of drug interactions and ultimately increases mortality and suicidal behaviors [27]. A systematic management program that is geared toward reducing polypharmacy in this population can improve patient safety and reduce hospitalizations from the burden of migraines [28].

PTHA presents a special challenge to remote populations with limited access to neurologic and medical care. This is problematic for deployed active duty service members who are expected to perform in any environment [3, 29–32]. Physical limitations are especially consequential, as they can increase use of medical resources, decrease productivity, and ultimately affect the military mission as a whole. We present an active duty and dependent population in the remote Pacific with post-traumatic headache or chronic post-traumatic headache who benefited from a unified multidimensional approach. Our intervention focused on lifestyle modifications, stress-management, and polypharmacy reduction in order to reduce migraine burden, improve quality of life, and decrease healthcare resource expenditure.

Methods
We collected data using a protocol that retrospectively reviewed a remote Neurology clinic’s systematic approach to treating PTHA and CPTHA. The study was approved through NAVMED West, Okinawa Naval Hospital institutional review board and complied with all ethical guidelines. Our selected population consisted of patients presenting to the Neurology Clinic at Naval Hospital Okinawa between September 2014 and December 2015. Chart review was performed on all patients over age 18 who were active duty or an active duty dependent with a diagnosis of headache or migraine in the electronic medical record (EMR). These diagnoses were made by a single Neurologist at Okinawa Naval Hospital based on Department of Defense (DoD) guidelines. Two hundred twenty-one patients presented to Neurology clinic and were diagnosed with headache or migraine over this timeframe. All patients were required to have persistence of headaches for >4–6 weeks after initial treatment by a primary care provider or traumatic brain injury specialist. The cohort was further stratified based on development or worsening of headache symptoms within 7 days after mild traumatic brain injury. Mild traumatic brain injury was defined as traumatically induced injury or disruption of brain function with normal structural imaging and less than 30 min loss of consciousness [33]. All patients met criteria for outpatient management of traumatic brain injury and were screened for underlying secondary headache disorder or intracranial complications, in which case they were excluded. At the time of presentation to the Neurology clinic, all service members were facing the possibility of duty restrictions or medical separation.
Over 1 year, patients seen in Neurology clinic for mild TBI, headache or migraine were provided didactics on pathophysiology of migraines, tension-type headaches and on post-traumatic headaches. Didactics discussed the importance of a multidimensional approach to management, focusing on both pharmacotherapy and non-pharmacotherapy options. We discussed the benefits and limitations of medications in treatment of headaches. The importance of lifestyle modifications was discussed. This included oral hydration therapy (i.e. one 16-oz electrolyte drink each morning prior to starting work), improvements in sleep hygiene and stress reduction. Patients were encouraged to keep a stable sleep schedule and were instructed to find a relaxing activity 30 min prior to sleep. Stress-reduction was encouraged through cognitive-behavioral therapy, biofeedback and meditation exercises. Each patient was provided a pamphlet summarizing these recommendations which was reviewed with the Neurologist during the clinic visit. Finally, patients were encouraged to engage in reduction of polypharmacy, as able. Down-titration or discontinuation of either abortive or preventative medications used for treatment of headache was guided by the Neurologist. Botulinum toxin was offered as an adjunctive treatment to assist in reduction of polypharmacy, but was only utilized in 2/25 PTHA or CPTHA patients. Pregnant patients were not offered Botulinum toxin, but within the PTHA / CTPHA cohort, there were none.

Patients had follow-up scheduled in Neurology clinic, TBI clinic and with primary care providers for migraine headaches. Other providers within the Okinawa Naval Hospital were educated about TBI and migraines through CME courses, telemedicine, Radio Broadcast shows, and community health fairs lead by the central Neurologist. All physicians were encouraged to advocate for lifestyle modification and polypharmacy reduction in migraine patients. At each Neurology visit, migraine severity, frequency, duration, and updated medication regimens were assessed and subjective quality of life (self-report of patient’s improvement) was documented in the EMR. A patient’s ability to perform at work was evaluated and the decision to medically board or restrict job assignment was made.

Participants in the study consented to implementing lifestyle modifications and were in agreement with the plan to reduce medication regimens as able. All personal information was de-identified in accordance with HIPPA regulations (Health Insurance Portability and Accountability Act of 1996). For PTHA and CPTHA patients, data was retrospectively collected starting 1 month after injury, for 2 years prior to intervention in Neurology clinic. Data collection was from EMR notes at each visit with a documented chief complaint of headache or migraine. It was also prospectively collected 2 years after intervention.

Data collected included demographics, migraine frequency, duration and severity, quality of life, current deployment and duty status, and current pharmacotherapy. Medications reviewed included pain medications (i.e. Gabapentin, non-steroidal anti-inflammatory agents (NSAIDS), and opioids) and headache preventative and abortive pharmacotherapies. The preventative agents included were Topiramate, Nortriptyline, Propranolol, Amitriptyline, Gabapentin, Clonidine, Verapamil, Venlafaxine and Indomethacin. The abortive medications included were Triptan agents, non-steroidal anti-inflammatory agents (NSAIDS), Naproxen Butalbital/Acetaminophen/Caffeine. Anti-emetics and supplements were excluded from this calculation.

In this study, each patient served as his or her own control. Data was collected and analyzed through a protected version of Excel. Descriptive statistics was used to summarize demographic and clinical characteristics. Chi-squared testing was used to determine statistical significance for categorical variables.

Results

Data collection included 221 patients who were treated by a single Neurologist over 806 appointments. Of these, 22 active duty service members (AD) and 3 Dependents suffered a mild traumatic brain injury, leading to post-traumatic headaches or chronic-post traumatic headaches. All patients with PTHA or CPTHA had headaches which persisted for greater than 4 weeks after initial injury in order to meet inclusion criteria. Patient’s average age was 29 years old, of predominantly male sex (68%), and primarily active duty (89%). Thirty two percent of patients had CPTHA (headache > 15 days per month). 32% of patients were on 2 or more medications at the time of initial evaluation. Sixty four percent of patients were diagnosed and treated for a coinciding psychiatric disorder, which included adjustment disorder, major depressive disorder, generalized anxiety disorder, or post-traumatic stress disorder (PTSD) (Table 1).

Table 1 Demographics of patients enrolled

| LOC (n = 13) | NO LOC (n = 12) |
|-------------|----------------|
| Average Age | 29             | 28             |
| Male sex    | 64%            | 73%            |
| Active duty | 93%            | 82%            |
| Dependent   | 7%             | 18%            |
| TBI mech    | 21% IED Blast, 14% Syncope | 18% IED blast, 9% Syncope |
| % Chronic migraine | 43% | 18% |
| >/= 2 meds at initial visit (p < .010) | 50% | 9% |
| Psychiatric diagnosis (p < .010) | 79% | 45% |
| Line of duty | 64%           | 55%           |
All patients included in our demographic sustained a mild traumatic brain injury. TBI occurred 10 years to 1 month prior to intervention. The average time from injury was 26 months. 52% of patients were greater than 1 year and two patients were greater than 10 years from injury. All patients had been treated by other providers for PTHA or CPTHA prior to presentation to the Neurology clinic. Mechanisms for TBI were varied, with 20% from IED or blast, 32% occurring from other trauma associated with line of duty, 24% secondary to fall or syncope, 20% sustained from recreational activity, and 8% from assault (Fig. 1). More than half of injuries involved loss of consciousness. Patients who sustained a mild TBI with loss of consciousness were significantly more likely to be on more than one medication for PTHA or CPTHA at time of presentation. They were also more likely to have psychiatric comorbidities.

After the first appointment with Neurology clinic, only 3 patients of 25 were started on an additional pain medication, abortive or preventative migraine medication. The patients who were started on new medications were all seen in Neurology clinic within 6 months of traumatic brain injury. However, they did not significantly differ from the population in regards to duty status, comorbid conditions, or outcome measures. Six patients (24%) were titrated down or discontinued from prior medications. The other patients (68%) were maintained on their current number of medications (Fig. 2).

After intervention, there was a 36% decrease in headache frequency and 56% decrease in headache severity within the PTHA / CPTHA cohort. Sixty percent of patients had reports of improved quality of life as compared to the 2 years prior to intervention (Fig. 3). Average appointments made per year for migraine or headache decreased from 6.8 to 2.6 after intervention, representing more than a 250% decrease in appointment frequency (Fig. 4). Of the cohort, 79% of patients had a decrease in appointment frequency (Fig. 5). The majority of patients (84%) were able to remain active duty and working in full capacity in Okinawa, Japan. Of the 25 patients treated for PTHA or CPTHA, four had a medical board initiated over the 2 years of evaluation and treatment, indicating they were no longer able to function in a military operational capacity. They were returned to the United States from Okinawa due to restrictions of job performance and to pursue further treatment. Two of the four patients were medically boarded for migraines, one for dysautonomia and one for a cardiac condition.

Discussion
This data represented the first cohort published with benefit from a systematic approach to the treatment of PTHA and CPTHA. Despite the small sample size, the pilot study demonstrated reduction in migraine frequency, intensity, and duration (Fig. 3). Encounters, including outpatient appointments and emergency room visits, were also reduced, minimizing the resource
utilization from PTHA/CPTHA treatment. Although it is suspected that a reduction in encounter visits demonstrated improvement in headache burden, this observation may have had other causes, including perception of limited utility or limited appointment availability. In future studies, scheduled phone calls may be useful to further investigate this cause.

In our cohort, nearly 90% of patients were prevented from increasing polypharmacy and nearly one quarter of patients were weaned or discontinued from medications (Fig. 2). However, since most patients were still taking medications and we did not compare to the natural history of PTHA/ CPTHA, this intervention of interest is less clear. Patients who sustained a mild traumatic brain injury with loss of consciousness were significantly more likely to have been started on 2 or more medications for headache prior to presentation to Neurology. They were also significantly more likely to have coinciding psychiatric comorbidities. The causal relationship is not known, and it is possible that the psychiatric comorbidities are what led to increased polypharmacy. However, it is also possible that providers are more willing to prescribe pain and headache medications in the setting mTBI with loss of consciousness. Given unique efforts from our single Neurologist, medication reduction was believed to be more prominent in our cohort than in other CTPHA and PTHA populations. It was therefore considered an intervention that contributed to outcome measures. In future research, it would be useful to compare this treatment method to patients treated by other providers who did not emphasize polypharmacy reduction.

Outcome measures included migraine frequency, severity and duration. Data was obtained from the electronic medical record and assumes accurate and detailed documentation. Pain scales were based on pain at time of clinic visit or included in reference to pain at times of migraine. This may be altered due to the tendency to present to clinic during times of headache or increased pain. Quality of life was also assessed, which was self-reported and documented in medical records. In future research, we would standardize the form of data collection and utilize well-accepted outcome measures for migraines, including the headache-impact scale. Additionally, our data set assumes improved outcomes are due to intervention performed within the Neurology clinic. However, many patients were undergoing coinciding psychiatric treatment which may have introduced
uncontrolled confounders. Psychiatric co-morbidities had a high prevalence among our cohort (64%) and the interplay between mental health and PTHA / CPTHA is widely recognized [33, 34]. Coinciding psychiatric treatments were encouraged, and could have altered our outcomes. Future studies would benefit from inclusion of psychiatry records and depression scales to better assess correlation between migraine improvement and improvement of psychiatric comorbidities.

In our cohort, 84% of patients were able to remain active duty and deployable. Although there is no published comparison for the number of patients with PTHA/CTPHA who are medically separated from the military each year, this is an accepted success within the given population. These results are ultimately a marker of reduced separation from the military, limitations of duty, or return to the United States from a deployed, overseas setting.

Despite recognized benefits of this systematic approach, there were evident flaws in data collection and outcome measures. First, we recognize that this is a small sample size which increases the possibility for a skewed dataset. It favored a younger patient population and was primarily active duty, deployed service members. However, we hope this study can serve as a framework for future research with a larger population. In future research, we would further subdivide patients based on PTHA and CPTHA subtype and we would stratify by time from injury. We would recommend use of headache diaries in order to better assess headache subtype and possible triggers. Secondly, this was an observational study, with comparisons made among the same group before and after intervention. Without a control group, it is hard to assess the natural progression of headache after TBI and our intervention was not independently assessed. Even without intervention, we may expect an improvement in headache burden as time increases from traumatic brain injury [35–37]. In order to minimize the more significant early improvements, we started data collection greater than 1 month from inciting trauma. Future research may benefit from stratifying patient population based on time from traumatic brain injury.

There are no consensus guidelines or FDA-approved medications for management of PTHA or CPTHA. The lack of a systematic approach ultimately promotes polypharmacy, leading to increased disability and mortality in this population [6, 16, 28, 38–48]. Our study focused on hydration, lifestyle changes, and biofeedback in lieu of pharmaceuticals, which seemed to have an impact on reducing clinic visits and improving quality of life. Hydration has a well-known benefit for sufferers, but is a relatively new treatment strategy for PTHA and CPTHA [6, 22, 49, 50]. This study is the first to formally implement a hydration and lifestyle approach, and initial results in CPTHA and PTHA are promising.

**Conclusions**

A combined multidisciplinary approach to treatment is likely to be most efficacious in the treatment of chronic post-traumatic headache and post-traumatic headache, especially in the military population given known lifestyle stressors and risk of TBI. Our goal was to improve quality of life and reduce disability, time away from work, hospitalizations, and polypharmacy in this population. This was made possible by having a central source of care, a single neurologist, and a collaborative effort with all providers through telemedicine in order to provide follow-up and continuity of care in a deployed setting in Okinawa, Japan.

This pilot study and its limitations will serve as a foundation for design of future research. The design and systematic approach will be used in a larger cohort, when we are able to stratify patients based on psychiatric comorbidities, more deliberate medication reduction, headache subtype and by time from initial traumatic brain injury. Our results can serve as a basis for instituting a systematic approach focused on lifestyle intervention, stress management and polypharmacy reduction in patients with post-traumatic headache and chronic post-traumatic headache. Flaws and shortcomings as documented above will be taken into account in future research, in order to enhance the credibility of the study and further illuminate the true effects of intervention. We believe that instituting such an approach on a larger scale would provide more definitive data on this approach for PTHA and CPTHA.

**Abbreviations**

AD: Active duty; CBT: Cognitive behavioral therapy; CPTHA: Chronic post-traumatic headache; EMR: Electronic medical record; FDA: Federal Drug Association; HIPPA: Health Insurance Portability and Accountability Act of 1996; NSAIDS: Non-steroidal anti-inflammatories; PTHA: Post-traumatic
headache; PTSD; post-traumatic stress disorder; QOL: Quality of life; TBI: Traumatic brain injury.

Acknowledgements
We would like to thank the American Academy of Neurology Palatucci program for their guidance.

Other
This data was presented as a poster at the American Academy of Neurology Annual Meeting 2018. The views expressed are solely those of the authors and does not reflect that of the U.S Government or the Department of Defense.

Funding
There are no funding sources to declare.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
VB analyzed and interpreted the patient data regarding migraine outcomes and demographics. KE assisted in data collection. NH was involved in patient treatment and data collection and was responsible for project design and supervision. NH and VB were the major contributors to writing the manuscript. NH and VB contributed equally to this paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Authors received the approval of NAVMED West Okinawa Naval Hospital Institutional Review Board on January 13th, 2016. Qi2016:0021. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Neurology, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20889, USA. 2Department of Anesthesiology, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD 20889, USA.

Received: 14 September 2018 Accepted: 4 November 2018

Published online: 22 November 2018

References
1. Kumar KG et al (2018) The effects of post-traumatic depression on cognition, pain, fatigue, and headache after moderate-to-severe traumatic brain injury: a thematic review. Brain Inj 32(4):383–394
2. Selassie AW et al (2013) Incidence of sport-related traumatic brain injury and risk factors of severity: a population-based epidemiologic study. Ann Epidemiol 23(2):750–756
3. Nampiaparampil DE et al (2008) Prevalence of chronic pain after traumatic brain injury: a systematic review. JAMA Neurol 66:1004–1021
4. Winkler et al (2016) Adult sports-related traumatic brain injury in United States trauma centers. Neurosurg Focus 40(4):E4
5. Headache Classification Committee of the International Headache Society (HIS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 2018. 38(1): p. 1–211
6. Theeler BJ, Flynn FG, Erickson JC (2012) Chronic daily headache in U.S. soldiers after concussion. Headache: The Journal of Head and Face Pain 52(7):732–738
7. Couch JR, Stewart KE (2016) Headache prevalence at 4-11 years after deployment-related traumatic brain injury in veterans of Iraq and Afghanistan wars and comparison to controls: a matched case-controlled study. Headache 56(6):1004–1021
8. Bomyea J et al (2016) Neuropsychiatric predictors of post-injury headache after mild-moderate traumatic brain injury in veterans. Headache 56(4):699–710
9. Willenman-son AH et al (2007) Prognostic factors of long-term functioning and productivity after traumatic brain injury: a systematic review of prospective cohort studies. Clin Rehabil 21(11):1024–1037
10. Mac Donald CL et al (2017) Early clinical predictors of 5-year outcome after concussive blast traumatic brain injury. JAMA Neurol 74(7):821–829
11. Vanderploeg RD, Belanger HG, Curtis G (2009) Mild traumatic brain injury and posttraumatic stress disorder and their associations with health symptoms. Arch Phys Med Rehabil 90(7):1084–1093
12. Kulas JF, Rosenheck RA (2018) A comparison of veterans with post-traumatic stress disorder, with mild traumatic brain injury and with both disorders: understanding multimorbidity. Mil Med 183(3–4):e114–e122
13. Campbell DA, Hay KM, Tonks EM (1951) Salt and water balance in migraine. Br Med J 2:1424–1429
14. Gurr B, Coetzter BR (2005) The effectiveness of cognitive-behavioural therapy for post-traumatic headaches. Brain Inj 19(7):481–491
15. Hickling E et al (1992) Headaches and motor vehicle accidents: results of the psychological treatment of post-traumatic. Headache 3285–289
16. Dindo L et al (2014) One-Day Behavioral Intervention in Depressed Migraine Patients: Effects on Headache. Headache 54(5):25–33
17. Watanabe TK et al (2012) Systematic review of interventions for post-traumatic headache. Pain r 4(2):129–140
18. Gaul C et al (2011) Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. J. Headache Pain 12(4):475–483
19. John Pj et al (2007) Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial. Headache 47(5):654–661
20. Diamond M, Cady R (2005) Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care. Am J Med 118:18–27
21. Lucas S (2015) Posttraumatic headache: clinical characterization and management. Curr Pain Headache Rep 19(10):48
22. Heyer GL, Idris SA (2014) Does analgesic overuse contribute to chronic post-traumatic headaches in adolescent concussion patients? Pediatr Neurol 50(5):464–468
23. DiTommaso C et al (2014) Medication usage patterns for headache and associated symptoms in symptomatic traumatic brain injury and neurologic populations. Arch Phys Med Rehabil 95(2):185–189
24. Morgan et al (2012) Pharmacotherapy regimens among patients with traumatic headaches in adolescent concussion patients? Pediatr Neurol 50(5):464–468
25. Mohamed S, Rosenheck RA (2008) Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. J Clin Psychiatry 69(6):959–965
26. Morgan M et al (2012) Pharmacotherapy regimes among patients with post-traumatic stress disorder and mild traumatic brain injury. Psychiatr Serv 63(2):182–185
27. Collett GA et al (2016) Prevalence of central nervous system polypharmacy and associations with overdose and suicide-related behaviors in Iraq and Afghanistan wars and comparison to controls: a matched case-controlled study. Headache 56(6):1004–1021
28. Conner MB et al (2005) Mild traumatic brain injury: a neuropsychiatric approach to diagnosis, evaluation, and treatment. Neuropsychiatr Dis Treat 1(4):311–327
29. Lahz S, Bryant RA (1996) Incidence of chronic pain following traumatic brain injury. Arch Phys Med Rehabil 77(10):889–891
30. Uomoto JM, Esselman PC (1993) Traumatic brain injury and chronic pain: differential types and rates by head injury severity. Arch Phys Med Rehabil 74(1):61–64
31. Brittain JT, Guilmette TJ, Sparadeo FR (1996) Sleep and pain complaints in symptomatic traumatic brain injury and neurologic populations. Arch Phys Med Rehabil 77(12):1298–1302
32. Defrin R (2014) Chronic post-traumatic headache: clinical findings and possible mechanisms. J. Man. Manip. Ther. 22(1):36–43
33. Juang KD, Yang C-Y (2014) Psychiatric comorbidity of chronic daily headache: focus on traumatic experiences in childhood, post-traumatic stress disorder and suicidality. Curr Pain Headache Rep 18(4):405
34. Friedman LE et al (2017) A systematic review and meta-analysis of migraine and suicidal ideation. Clin J Pain 33(7):659–665
35. Hoffman JM et al (2011) Natural history of headache after traumatic brain injury. J Neurotrauma 28(8):1719–1725
36. Lucas S et al (2014) A prospective study of prevalence and characterization of headache following mild traumatic brain injury. Cephalalgia 34(2):93–102
37. Walker WC et al (2013) Prediction of headache severity (density and functional impact) after traumatic brain injury: a longitudinal multicenter study. Cephalalgia 33(12):998–1008
38. Marmura Michael J, Silberstein Stephen D, Schwedt Todd J (2015) The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache: The Journal of Head and Face Pain 55(1):3–20
39. McIntire K et al (2017) Mild traumatic brain injury (mTBI) and chronic cognitive impairment: a scoping review. PLoS One 12(4):e0174847
40. McCrea M et al (2013) Incidence, clinical course, and predictors of prolonged recovery time following sport-related concussion in high school and college athletes. J Int Neuropsychol Soc 19(1):22–33
41. McCrea M et al (2003) Acute effects and recovery time following concussion in collegiate football players: the ncaa concussion study. JAMA 290(19):2556–2563
42. Ponsford J et al (2011) Long-term outcomes after uncomplicated mild traumatic brain injury: a comparison with trauma controls. J Neurotrauma 28(6):937–946
43. Choe, M., The pathophysiology of Concussion Vol. 20. 2016
44. Yerry JA, Kuehn D, Finkel AG (2015) Onabotulinumtoxin a for the treatment of headache in service members with a history of mild traumatic brain injury: a cohort study. Headache: The Journal of Head and Face Pain 55(3):395–406
45. Conidi FX (2016) Interventional treatment for post-traumatic headache. Curr Pain Headache Rep 20(6):40
46. Stephen S et al (2008) Epidemiology, risk factors, and treatment of chronic migraine: a focus on Topiramate. Headache: The Journal of Head and Face Pain 48(7):1087–1095
47. Pistola F, Sacco S, Carolei A (2012) Behavioral therapy for chronic migraine. Curr Pain Headache Rep 17(1):304
48. Dodick David W et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache: The Journal of Head and Face Pain 50(6):921–936
49. Lucas S (2011) Headache Management in Concussion and Mild Traumatic Brain Injury. PM&R 3(10):S406–S412
50. Kwentus JA et al (1985) Psychiatric complications of closed head trauma. Psychosomatics 26(1):8–17